Please use this identifier to cite or link to this item:
Title: Circulating miRNAs signature on breast cancer: the MCC-Spain project
Author: Gómez Acebo, Inés
Llorca, Javier
Alonso Molero, Jessica
Díaz Martínez, Marta
Pérez Gómez, Beatriz
Amiano, Pilar
Belmonte, Thalía
Molina, Antonio J.
Burgui, Rosana
Castaño Vinyals, Gemma
Moreno Aguado, Víctor
Molina Barceló, Ana
Marcos Gragera, Rafael
Kogevinas, Manolis
Pollán, Marina
Dierssen Sotos, Trinidad
Keywords: RNA
Càncer de mama
Breast cancer
Issue Date: 4-Nov-2023
Publisher: Springer Science and Business Media LLC
Abstract: PurposeTo build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer.MethodmiRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization.ResultsThe model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82.ConclusionWe present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported.
Note: Reproducció del document publicat a:
It is part of: European Journal of Medical Research, 2023, vol. 28, num. 1
Related resource:
ISSN: 2047-783X
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s40001-023-01471-2.pdf1.92 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons